An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aura Biosciences to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotech firm, focuses on developing virus-like drug conjugate (VDC) therapies for oncology. CEO Elisabet de los Pinos will present at the SVB Securities Global Biopharma Conference on February 16, 2023 at 12:00 p.m. ET and at the 43rd Annual Cowen Healthcare Conference on March 8, 2023, participating in an auditory and ophthalmology panel at 12:50 p.m. ET. These events will be accessible via live webcasts on Aura's website, where replays will be available for 90 days.
Aura's lead VDC candidate, bel-sar, targets ocular cancers and is in a Phase 3 trial for treating early-stage choroidal melanoma.
Positive
None.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences:
SVB Securities Global Biopharma Conference on Thursday, February 16, 2023.
Fireside Chat at 12:00 p.m. ET.
43rd Annual Cowen Healthcare Conference on Wednesday, March 8, 2023.
Auditory & Ophthalmology Panel Discussion at 12:50 p.m. ET.
Live webcasts of the SVB fireside chat and Cowen panel discussion will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, belzupacap sarotalocan (bel-sar; AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Bel-sar is designed to selectively target and destroy cancer cells and activate the immune system with the potential to create long-lasting anti-tumor immunity. Bel-sar is currently in development for ocular cancers, and Aura has initiated activities for the global Phase 3 trial evaluating first-line treatment of early-stage choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to pursue development of bel-sar across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura’s technology platform, Aura is developing bel-sar more broadly across multiple cancers, including in patients with non-muscle invasive bladder cancer (NMIBC). Aura is headquartered in Boston, MA.
What conferences will Aura Biosciences participate in 2023?
Aura Biosciences will participate in the SVB Securities Global Biopharma Conference on February 16 and the Cowen Healthcare Conference on March 8, 2023.
What is the date and time for the SVB Securities Global Biopharma Conference presentation?
The SVB Securities Global Biopharma Conference presentation is scheduled for February 16, 2023, at 12:00 p.m. ET.
What is the focus of Aura Biosciences’ lead candidate bel-sar?
Bel-sar is designed to selectively target and destroy cancer cells, focusing on ocular cancers, particularly in a Phase 3 trial for early-stage choroidal melanoma.
How can I access the live webcasts for Aura Biosciences' presentations?
Live webcasts can be accessed on Aura Biosciences' 'Investors & Media' page under the 'Events & Presentations' section of their website.
What is the aim of Aura's Phase 3 trial for bel-sar?
The Phase 3 trial aims to evaluate bel-sar as a first-line treatment for early-stage choroidal melanoma.
